A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2023-02-04
Adverse events
Grade 3 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-03-29 (study day 37); relationship: not assessed
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-04-27 (study day 66); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-07-27 (study day 157); relationship: not assessed
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-08-19 (study day 180); relationship: not assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-11-09 (study day 262); relationship: Y
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-12-04 (study day 287); relationship: Y
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-12-24 (study day 307); relationship: N
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-03-12 (study day 386); relationship: Y
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-05-11 (study day 446); relationship: not assessed
Data queries
No data queries.